Superiority trials | Noninferiority trials | P-value* | |||||
---|---|---|---|---|---|---|---|
Standardized difference | No. | P-value | Standardized difference | No. | P-value | ||
Year of publication | |||||||
2004-2006 | 0.46 (0.23) | 59 | 0.42 | 0.28 (0.13) | 59 | 0.40 | 0.72 |
2007-2009 | 0.42 (0.30) | 41 | - | 0.30 (0.12) | 41 | - | - |
Medical context | 0.38 | 0.001 | 0.006 | ||||
Cardiovascular | 0.36 (0.22) | 14 | 0.18 (0.09) | 19 | |||
Infectious diseases | 0.51 (0.11) | 3 | 0.33 (0.08) | 23 | |||
Oncology | 0.44 (0.23) | 6 | 0.26 (0.008) | 10 | |||
Other | 0.47 (0.27) | 77 | 0.31 (0.14) | 48 | |||
Pharmacological trial | |||||||
Yes | 0.44 (0.28) | 54 | 0.76 | 0.29 (0.12) | 73 | 0.99 | 0.77 |
No (other area) | 0.46 (0.24) | 46 | - | 0.29 (0.15) | 27 | - | - |
Patients age-group | 0.43 | 0.46 | |||||
Children < 18 yrs | 0.51 (0.18) | 18 | 0.31 (0.10) | 18 | 0.41 | ||
Adults | 0.44 (0.28) | 77 | 0.28 (0.13) | 82 | - | ||
Elderly | 0.35 (0.13) | 5 | - | 0 | - | ||
Mortality outcome | |||||||
Yes | 0.28 (0.17) | 11 | 0.02 | 0.17 (0.09) | 17 | <0.001 | <0.001 |
No | 0.47 (0.26) | 89 | - | 0.31 (0.12) | 83 | - | - |
Statistician involved | |||||||
Yes | 0.44 (0.27) | 46 | 0.83 | 0.28 (0.14) | 54 | 0.64 | 0.69 |
No | 0.45 (0.26) | 54 | - | 0.29 (0.10) | 46 | - | - |
Patients' recruitment | |||||||
Multicenter | 0.38 (0.21) | 67 | <0.001 | 0.28 (0.12) | 88 | 0.02 | <0.001 |
Single-center | 0.58 (0.30) | 33 | - | 0.36 (0.16) | 12 | - | - |
Funding source | 0.18 | 0.95 | 0.19 | ||||
Industry | 0.40 (0.22) | 50 | 0.29 (0.12) | 70 | |||
Institution/private | 0.47 (0.32) | 33 | 0.28 (0.14) | 25 | |||
Not reported/funded | 0.53 (0.23) | 17 | 0.29 (0.09) | 5 | |||
Sample size ≤200 | 0.67 (0.25) 0.42 (0.10) | 37 27 | 0.38 (0.13) 0.36 (0.09) | 10 23 | |||
200-400 | 0.28 (0.07) | 14 | <0.001 | 0.28 (0.09) | 38 | <0.001 | ** |
400-800 | 0.18 (0.13) | 20 | 0.20 (0.14) | 28 | |||
>800 |